Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320590 | 0.81 | CNR1 (0.40) | KMT2AMAPTKDM4EALDH1A1CES1 | |
| SCHEMBL2319012 | 0.81 | ALDH1A1 (0.42) | KMT2AMAPTKDM4EALDH1A1TP53 | |
| SCHEMBL2321465 | 0.80 | MAOB (0.45) | MAPTKDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL2314915 | 0.78 | TRPM8 (0.39) | KMT2AMAPTKDM4EALDH1A1TP53 | |
| SCHEMBL19682380 | 0.76 | KDM4E (0.43) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31111205 | 0.76 | KDM4E (0.43) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12686317 | 0.74 | CNR2 (0.44) | KMT2AMAPTKDM4EALDH1A1TP53 | |
| SCHEMBL1508423 | 0.72 | PARP1 (0.50) | KMT2ACES1MEN1NOTUMMETAP1 | |
| SCHEMBL20889275 | 0.72 | CHRM2 (0.41) | KMT2AMAPTKDM4EALDH1A1CES1 | |
| SCHEMBL2321373 | 0.70 | ALDH1A1 (0.46) | KMT2AMAPTKDM4EALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2352726-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2352727-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | disclosed |
| CN-101827585-A | Solid dispersion product containing N-aryl ureido compound | ABBOTT GMBH & CO KG | 2010-09-08 | — | — | CN | disclosed |
| EP-2197426-A2 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | Abbott GmbH & Co. KG (DE) | 2010-06-23 | — | — | EP | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045401-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045402-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
| WO-2009050289-A2 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | KMT2A 4113/4885MAPT 1697/4885KDM4E 3931/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | KMT2A 4177/4885MAPT 1871/4885KDM4E 4032/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | KMT2A 1695/4885MAPT 296/4885KDM4E 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.